This is an aggregated industry headline. Read the full story at BioPharma Dive →
ASCO '26: Bispecifics vs. ADCs, a 'RAS' revolution and a step change in prostate cancer
At the year's biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
By BioPharma Dive
· Jun 2, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Foundation Medicine has started the "Quality First" initiative to create awareness of how "not all cancer biom…
The WeekFierceBiotech ↗
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major…
The WeekPharmaceutical Technology ↗
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.…